Join Growin Stock Community!

長聖6712.TW Overview

TW StockBiotech. & Medical
(No presentation for 6712)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

長聖(6712)Overall Performance

長聖(6712)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

長聖(6712) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

長聖(6712)Key Information

長聖(6712)Profile

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company was incorporated in 2016 and is based in Taichung, Taiwan.

長聖(6712)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
37.38
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
69.95%
Net Margin
51.78%
Revenue Growth (YoY)
12.62%
Profit Growth (YoY)
10.35%
3-Year Revenue Growth
19.92%
3-Year Profit Growth
24.47%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
37.38
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
69.95%
Net Margin
51.78%
Revenue Growth (YoY)
12.62%
Profit Growth (YoY)
10.35%
3-Year Revenue Growth
19.92%
3-Year Profit Growth
24.47%
default symbol

6712

長聖

145.50D

-3.09%

(-0.03)

  • When is 6712's latest earnings report released?

    The most recent financial report for 長聖 (6712) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6712's short-term business performance and financial health. For the latest updates on 6712's earnings releases, visit this page regularly.

  • Where does 6712 fall in the P/E River chart?

    According to historical valuation range analysis, 長聖 (6712)'s current price-to-earnings (P/E) ratio is 29.22, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 6712?

    According to the latest financial report, 長聖 (6712) reported an Operating Profit of 105.02M with an Operating Margin of 39.9% this period, representing a growth of 11.16% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6712's revenue growth?

    In the latest financial report, 長聖 (6712) announced revenue of 263.2M, with a Year-Over-Year growth rate of 6.08%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6712 have?

    At the end of the period, 長聖 (6712) held Total Cash and Cash Equivalents of 210.02M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6712 go with three margins increasing?

    In the latest report, 長聖 (6712) achieved the “three margins increasing” benchmark, with a gross margin of 67.29%%, operating margin of 39.9%%, and net margin of 49.96%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6712's profit trajectory and future growth potential.

  • Is 6712's EPS continuing to grow?

    According to the past four quarterly reports, 長聖 (6712)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6712?

    長聖 (6712)'s Free Cash Flow (FCF) for the period is 37.04M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 208.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.